DiaMedica Therapeutics Inc. (DMAC) stock
Close on Nov 11, 2026Market cap $520.92MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $520.92M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 13.59
- Dividend yield
- –
- Free cash flow yield
- -6.06%
Fundamentals
- Net income
- -$37.54M
- EPS, diluted
- -$0.72
- Free cash flow
- -$31.54M
- Book value per share
- $0.71
- Diluted shares
- 54M
Trading
- Next earnings
- Nov 11, 2026 (estimated, during market hours)
- Previous close
- $9.67
- Open
- $9.72
- Day's range
- $9.53 – $9.85
- Volume
- 139,358
- Average volume (20 days)
- 216,847
- Index membership
- Russell 2000 (since Jun 2025)
- Beta (5 years)
- 1.02
- 52-week range
- $5.25 – $11.00
- RSI (14 days)
- 57.9
- Volatility (1 year)
- 60.9%
- Relative volume
- 0.73×
- WACC
- 10.0%
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | DMAC | S&P 500 | Difference | DMAC per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +16.0% | -2.4% | +18.4 pts | ||
| 3 months | +40.6% | -1.2% | +41.8 pts | ||
| Year to date | +21.4% | +12.3% | +9.1 pts | ||
| 1 year | +51.2% | +12.4% | +38.7 pts | ||
| 3 years | +309.3% | +78.8% | +230.5 pts | +60.0% | +21.4% |
| 5 years | +113.2% | +75.2% | +38.1 pts | +16.4% | +11.9% |
| 10 years | +144.9% | +311.1% | −166.2 pts | +9.4% | +15.2% |
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases DiaMedica Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
About DiaMedica Therapeutics
Pharmaceutical Preparations
The company is a clinical-stage biopharmaceutical business developing protein therapies for individuals suffering from severe ischemic conditions. Its lead product candidate is DM199, a recombinant synthetic form of human tissue kallikrein-1 designed to improve blood flow, vascular health, and tissue perfusion. The firm focuses on clinical programs targeting preeclampsia and fetal growth restriction in pregnant women, as well as acute ischemic stroke. In addition, the organization maintains an early-stage development candidate, DM300, aimed at treating severe acute pancreatitis. Its prospective end users are patients experiencing these vascular and ischemic diseases.
Company profile, executives and historyDiaMedica Therapeutics stock: common questions
What is DiaMedica Therapeutics's stock price?
DMAC closed at $9.66 on Nov 11, 2026, down 0.10% on the day. Over the past 52 weeks it traded between $5.25 and $11.00.
What is DiaMedica Therapeutics's market cap?
DiaMedica Therapeutics was worth $520.92M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is DMAC's P/E ratio?
DiaMedica Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.72), so it has no meaningful P/E ratio.
Does DiaMedica Therapeutics pay a dividend?
No. DiaMedica Therapeutics has not paid a cash dividend over the last twelve months.
When does DiaMedica Therapeutics report earnings next?
DiaMedica Therapeutics is expected to report Q3 FY2026 results on Nov 11, 2026, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has DMAC stock performed over the past year?
Including dividends, DMAC returned +51.2% over the past year, against +12.4% for the S&P 500.
How many DMAC shares are sold short?
5M shares were sold short at the latest FINRA report, 10.60% of the float, or 24.8 days of average trading volume.
Who are DiaMedica Therapeutics's competitors?
Companies most similar to DiaMedica Therapeutics by business, industry and size include NAMS, LRMR, IRON, KROS, DNTH.
See a number that looks wrong?